Hatz, K.; Ambresin, A.; Schmid, M.; Prünte, C.; Barthelmes, D.; Machewitz, T.; Allmeier, H.; Somfai, G.M., on behalf of the XTEND Study Group.
Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration. J. Clin. Med. 2025, 14, 2370.
https://doi.org/10.3390/jcm14072370
AMA Style
Hatz K, Ambresin A, Schmid M, Prünte C, Barthelmes D, Machewitz T, Allmeier H, Somfai GM on behalf of the XTEND Study Group.
Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine. 2025; 14(7):2370.
https://doi.org/10.3390/jcm14072370
Chicago/Turabian Style
Hatz, Katja, Aude Ambresin, Martin Schmid, Christian Prünte, Daniel Barthelmes, Tobias Machewitz, Helmut Allmeier, and Gabor Mark Somfai on behalf of the XTEND Study Group.
2025. "Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration" Journal of Clinical Medicine 14, no. 7: 2370.
https://doi.org/10.3390/jcm14072370
APA Style
Hatz, K., Ambresin, A., Schmid, M., Prünte, C., Barthelmes, D., Machewitz, T., Allmeier, H., & Somfai, G. M., on behalf of the XTEND Study Group.
(2025). Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine, 14(7), 2370.
https://doi.org/10.3390/jcm14072370
